Incidence, risk factors, and outcomes of anti-tuberculosis drug-induced hepatotoxicity in people with and without HIV in Thailand and the Philippines
References
- World Health Organization. Global tuberculosis report 2024 [Internet]. Geneva: World Health Organization; 2024 [cited 2025 Jan 5]. Available from:
www.who.int/tb/publications/global_report/en/ - Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016; 13:e1002152. doi: 10.1371/journal.pmed.1002152
- Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014; 179:216–25. doi: 10.1093/aje/kwt246
- Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9:e1001270. doi: 10.1371/journal.pmed.1001270
- Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018; 16:46. doi: 10.1186/s12916-018-1033-7
- Coca NSM, Oliveira MS, Voieta I, Antunes CMF, Lambertucci JR. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity. Rev Soc Bras Med Trop. 2010; 43:624–8. doi: 10.1590/S0037-86822010000600004
- World Health Organization. Implementing the WHO stop TB strategy: a handbook for national TB control programmes [Internet]. Geneva: World Health Organization; 2008 [cited 2025 Jan 5]. Available from:
https://www.who.int/publications/i/item/9789241546676 - Department of Disease Control, Ministry of Public Health. NTP: national tuberculosis control programme guideline, Thailand [Internet]. Nonthaburi: Department of Disease Control, Ministry of Public Health; 2021 [cited 2025 Jan 5]. Available from:
https://ddc.moph.go.th/dtb/ - World Health Organization. Treatment of tuberculosis: guidelines [Internet]. Geneva: World Health Organization; 2010 [cited 2025 Jan 5]. Available from:
https://iris.who.int/handle/10665/44165 - Ali N, Gupta N, Saravu K. Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy: an experience from a tertiary care center in South India. Drug Discov Ther. 2020; 14:135–8. doi: 10.5582/ddt.2020.03029
- Schiuma M, Dinegro S, Battini V, Torre A, Covizzi A, Civati A, et al. NAT2 acetylation status predicts hepatotoxicity during antituberculosis therapy: cumulative risk analysis of a multiethnic cohort. Int J Mol Sci. 2025; 26:3881. doi: 10.3390/ijms26083881
- Assob JCN, Nde PF, Nsagha S, Njunda AL, Ngum NM, Ngowe MN. Incidence and risk factors of anti-tuberculosis drugs induced hepatotoxicity in HIV/AIDS patients attending the Limbe and Buea regional hospitals. J AIDS Clin Res. 2014; 5: 288. doi: 10.4172/2.155-6113.1000288
- Mo P, Zhu Q, Teter C, Yang R, Deng L, Yan Y, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis. 2014; 28:95–100. doi: 10.1016/j.ijid.2014.06.020
- World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions [Internet]. Geneva: World Health Organization; 2021 [cited 2025 Jan 5]. Available from: [
https://www.who.int/publications/i/item/9789240022195 ](https://www.who.int/publications/i/item/9789240022195 ). - Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia. BMC Res Notes. 2020; 13:2. doi: 10.1186/s13104-019-4872-1
- Hassen Ali A, Belachew T, Yami A, Ayen WY. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One. 2013; 8:e64622. doi: 10.1371/journal.pone.0064622
- Lima Mde F, Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica. 2012; 28:698–708. doi: 10.1590/S0102-311X2012000400009
- Kumar R, Kumar A, Patel R, Prakash SS, Kumar S, Surya H, et al. Incidence and risk factors of antituberculosis drug-induced liver injury in India: a systematic review and meta-analysis. Indian J Gastroenterol. 2025; 44:35–46. doi: 10.1007/s12664-024-01643-w
- Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, et al. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS One. 2008; 3:e1809. doi: 10.1371/journal.pone.0001809
- Neff GW, Jayaweera D, Sherman KE. Drug-induced liver injury in HIV patients. Gastroenterol Hepatol (N Y). 2006; 2:430–7.
- Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013; 381:735–43. doi: 10.1016/S0140-6736(12)61853-4
- Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients. PLoS One. 2014; 9:e94271. doi: 10.1371/journal.pone.0094271
- Wijting IEA, Wit FWNM, Rokx C, Leyten EMS, Lowe SH, Brinkman K, et al. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy. eClinicalMedicine. 2019; 17:100210. doi: 10.1016/j.eclinm.2019.11.003
- Psichogiou M, Basoulis D, Tsikala-Vafea M, Vlachos S, Kapelios CJ, Daikos GL. Integrase strand transfer inhibitors and the emergence of immune reconstitution inflammatory syndrome (IRIS). Curr HIV Res. 2017; 15:405–410. doi: 10.2174/1570162X15666171122155708
- Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2019; 70:549–56. doi: 10.1093/cid/ciz256
- Devarbhavi H, Aithal G, Treeprasertsuk S, Takikawa H, Mao Y, Shasthry SM, et al. Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines. Hepatol Int. 2021; 15:258–82. doi: 10.1007/s12072-021-10144-3
- Zhong T, Fan Y, Dong XL, Guo X, Wong KH, Wong WT, et al. an investigation of the risk factors associated with anti-tuberculosis drug-induced liver injury or abnormal liver functioning in 757 patients with pulmonary tuberculosis. Front Pharmacol. 2021; 12:2021. doi: 10.3389/fphar.2021.708522
- Ngouleun W, Biapa Nya PC, Pieme AC, Telefo PB. Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. Int J Mycobacteriol. 2016; 5:482–8. doi: 10.1016/j.ijmyco.2016.05.003
- Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013; 8:e83892. doi: 10.1371/journal.pone.0083892
- Wang N, Chen X, Hao Z, Guo J, Wang X, Zhu X, et al. Incidence and temporal trend of antituberculosis drug-induced liver injury: a systematic review and meta-analysis. J Trop Med. 2022; 2022:8266878. doi: 10.1155/2022/8266878
- Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998; 157(6 Pt 1):1871–6. doi: 10.1164/ajrccm.157.6.9711039
- Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest. 2007; 131:803–8. doi: 10.1378/chest.06-2042
- Ivanov AV, Bartosch B, Smirnova OA, Isaguliants MG, Kochetkov SN. HCV and oxidative stress in the liver. Viruses. 2013; 5:439–69. doi: 10.3390/v5020439
- Sirinak C, Kittikraisak W, Pinjeesekikul D, Charusuntonsri P, Luanloed P, Srisuwanvilai LO, et al. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Pub Health. 2008; 8:245. doi: 10.1186/1471-2458-8-245
- Araújo-Mariz C, Lopes EP, Acioli-Santos B, Maruza M, Montarroyos UR, Ximenes RA, et al. Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS. PLoS One. 2016; 11:e0157725. doi: 10.1371/journal.pone.0157725
- Messou E, Anglaret X, Bonard D, Kouabena H, N'Dri-Yoman T, Dosso M, et al. The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast. Br J Clin Pharmacol. 2001; 52:611–2. doi: 10.1046/j.0306-5251.2001.01483.x
- Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterol. 2017; 4:e000166. doi: 10.1136/bmjgast-2017-000166
- Tomich LG, Núñez M, Mendes-Correa MC. Drug-induced liver injury in hospitalized HIV patients: high incidence and association with drugs for tuberculosis. Ann Hepatol. 2015; 14:888–94. doi: 10.5604/16652681.1171778
- Molla Y, Wubetu M, Dessie B. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med. 2021; 13:1–8. doi: 10.2147/HMER.S290542
- Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008; 23:192–202. doi: 10.1111/j.1440-1746.2007.05207.x
- Cho FN, Achidi EA, Enoh JE, Pallerla SR, Linh LTK, Tong HV, et al. Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection. BMC Infect Dis. 2024; 24:759. doi: 10.1186/s12879-024-09638-w
- Naidoo S, Evans D, Jong E, Mellet K, Berhanu R. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. S Afr Med J. 2015; 105:393–6. doi: 10.7196/SAMJ.8217
- Boyles T, Berhanu RH, Gogela N, Gunter H, Lovelock T, Mphothulo N, et al. Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update. South Afr J HIV Med. 2024; 25:1558. doi: 10.4102/sajhivmed.v25i1.1558
- Ministry of Public Health, Department of Disease Control. National guideline on elimination of viral hepatitis B & C and elimination of mother-to-child transmission of hepatitis B virus [Internet]. Nonthaburi: Ministry of Public Health; 2023 [cited 2024 Dec 16]. Available from:
https://ddc.moph.go.th/uploads/publish/1466820230926064645.pdf
Language: English
Page range: 170 - 181
Published on: Jun 30, 2026
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Ryan Christopher Geturbos Atuel, Emmanuel A. Gutierrez, Napon Hiranburana, Tanakorn Apornpong, Sasiwimol Ubolyam, Ma. Tarcela S. Gler, Anchalee Avihingsanon, Sivaporn Gatechompol, Stephen J. Kerr, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.